Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ARRY Array BioPharma Inc. daily Stock Chart
ARRY [NASD]
Array BioPharma Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.59 Insider Own0.40% Shs Outstand223.43M Perf Week-0.79%
Market Cap10.32B Forward P/E- EPS next Y-0.35 Insider Trans-58.08% Shs Float220.96M Perf Month70.58%
Income-126.10M PEG- EPS next Q-0.15 Inst Own- Short Float12.42% Perf Quarter96.05%
Sales239.60M P/S43.09 EPS this Y-3.70% Inst Trans5.51% Short Ratio5.49 Perf Half Y240.03%
Book/sh1.37 P/B33.73 EPS next Y22.40% ROA-24.50% Target Price32.40 Perf Year138.56%
Cash/sh1.89 P/C24.40 EPS next 5Y10.00% ROE-49.20% 52W Range12.56 - 47.05 Perf YTD224.28%
Dividend- P/FCF- EPS past 5Y-5.30% ROI-41.80% 52W High-1.79% Beta1.73
Dividend %- Quick Ratio5.60 Sales past 5Y20.10% Gross Margin92.40% 52W Low267.91% ATR1.63
Employees298 Current Ratio5.70 Sales Q/Q-2.60% Oper. Margin-49.70% RSI (14)88.44 Volatility0.75% 2.42%
OptionableYes Debt/Eq0.44 EPS Q/Q-55.90% Profit Margin-52.60% Rel Volume1.30 Prev Close46.23
ShortableYes LT Debt/Eq0.44 EarningsAug 06 BMO Payout- Avg Volume5.00M Price46.21
Recom1.60 SMA2036.92% SMA5069.38% SMA200127.82% Volume6,507,189 Change-0.04%
Jan-17-19Initiated Leerink Partners Outperform $28
Dec-13-18Initiated Goldman Neutral $20
Feb-07-18Reiterated Stifel Buy $20 → $23
Jan-22-18Upgrade Leerink Partners Mkt Perform → Outperform
Jan-22-18Reiterated Stifel Buy $15 → $20
Sep-11-17Reiterated Stifel Buy $13 → $15
May-03-17Upgrade JP Morgan Neutral → Overweight
Feb-03-17Reiterated Stifel Buy $8 → $13
Feb-03-17Downgrade JP Morgan Overweight → Neutral
Jan-30-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-26-16Reiterated Piper Jaffray Overweight $7 → $10
Sep-26-16Reiterated Leerink Partners Outperform $6 → $9
Jan-26-15Reiterated Stifel Buy $6 → $9
Aug-09-13Reiterated Stifel Buy $7 → $8
Jul-23-10Upgrade UBS Neutral → Buy $4.25
Apr-22-10Downgrade UBS Buy → Neutral
Nov-05-09Upgrade UBS Neutral → Buy
Sep-08-09Downgrade UBS Buy → Neutral
Sep-04-09Downgrade Robert W. Baird Outperform → Neutral $10 → $3
Sep-04-09Downgrade Leerink Swann Outperform → Mkt Perform $6 → $2
Jun-25-19 10:32AM  Abbvie Decides to Acquire Allergan Zacks
10:14AM  AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20 Zacks
08:00AM  Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer PR Newswire
Jun-24-19 04:23PM  Why These Innovative Biotech ETFs Soaring Zacks
02:00PM  CJ, ARRY, BID INVESTOR ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - CJ, ARRY, BID ACCESSWIRE
11:45AM  Eldorado to Buy Caesars Zacks
10:06AM  U.S. Senate Takes on Big Tech, Plus "Merger Monday" Zacks
Jun-23-19 09:00AM  These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now? Motley Fool
Jun-21-19 08:00PM  URGENT ALERT: Monteverde & Associates PC Launches an Investigation Regarding the Following Merger PR Newswire
04:13PM  Stock Market Rally Soars On Fed, China Trade Hopes; Facebook Cryptocurrency, Boeing 737 Max Order, Adobe, Oracle Earnings Investor's Business Daily
03:12PM  Oh, By the Way, This Clinical Trial Didn't Work Motley Fool
10:01AM  3 Big Biotechs Hold Growth Potential in Second Half of 2019 Zacks
09:40AM  Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma Zacks
Jun-20-19 10:38AM  Is Pfizer Overpaying for Array Biopharma? Motley Fool
Jun-19-19 04:49PM  Here's Pfizer's Motivation Behind Its Biggest Takeover In 3 Years Investor's Business Daily
11:20AM  Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Zacks
09:27AM  A Beloved Biotech ETF Could Lure Traders Again Benzinga
09:06AM  Big Drugmakers That May Tread the M&A Path After Pfizer Zacks
Jun-18-19 05:57PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition PR Newswire
03:51PM  Papa Johns Auditor Swap Is Not a Good Look Motley Fool
09:55AM  Pfizer-Array Biopharma Deal Bump Up Biotech ETFs Zacks
09:51AM  Cancer Therapy Stocks Soar After Pfizer Deal Investopedia
09:51AM  Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio Zacks
09:35AM  Company News For Jun 18, 2019 Zacks
07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
02:07AM  PRESS DIGEST - Wall Street Journal - June 18 Reuters
Jun-17-19 06:14PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Array BioPharma Inc. (NASDAQ: ARRY) on Behalf of Array Shareholders and Encourages Array Investors to Contact the Firm GlobeNewswire +56.94%
05:06PM  What Happened in the Stock Market Today Motley Fool
05:00PM  Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon Motley Fool
04:48PM  How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers Investor's Business Daily
04:41PM  Dow Jones Today: Almost a Case of the Mondays InvestorPlace
04:23PM  Pfizer acquires Array in 2nd major Boulder bioscience merger this month American City Business Journals
04:17PM  Stocks close higher as social media, real estate shares lead MarketWatch
04:05PM  5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA InvestorPlace
03:23PM  Pfizer Is Buying Array BioPharma, Seeking to Broaden Lineup of Cancer Drugs Barrons.com
03:20PM  Pfizer Is the Latest Drug Company to Put Its Credit Rating at Risk With M&A Barrons.com
12:40PM  Pfizer Inc. -- Moody's: Pfizer's acquisition of Array is credit negative Moody's
12:11PM  Array BioPharma News: ARRY Stock Skyrockets on Pfizer Deal InvestorPlace
11:59AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Array BioPharma Inc. to Pfizer Inc. is Fair to Shareholders GlobeNewswire
10:46AM  Big Ticket Mergers Are in Focus Zacks
10:43AM  ARRAY BIOPHARMA INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout GlobeNewswire
10:33AM  "Merger Monday" Returns: Pfizer Buying Array, T-Mobile-Sprint on Ice? Zacks
10:30AM  Array Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Array BioPharma Inc. is Fair to Shareholders ARRY GlobeNewswire
09:35AM  Pfizer Expands in Cancer With $10.6 Billion Deal for Array Bloomberg
09:35AM  Stocks mixed as Fed meeting comes into view MarketWatch
09:32AM  Dish Stock Is Up as the Dow Squeaks Higher Barrons.com
09:26AM  Pfizer buys cancer treatment innovator Array BioPharma for $11 billion American City Business Journals
08:43AM  S&P places Pfizer ratings on CreditWatch negative after $11.4 billion Array deal MarketWatch
06:56AM  Pfizer bolsters cancer portfolio with $10.64 billion deal for Array Reuters
06:56AM  Array BioPharma's stock rockets after $11.4 billion buyout deal with Pfizer MarketWatch
06:54AM  Pfizer to Acquire Array BioPharma PR Newswire
Jun-12-19 09:34PM  Edited Transcript of ARRY earnings conference call or presentation 5-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
Jun-10-19 09:39AM  Here is What Hedge Funds Think About Array Biopharma Inc (ARRY) Insider Monkey
Jun-06-19 09:31AM  Why Is Array BioPharma (ARRY) Up 27.1% Since Last Earnings Report? Zacks
Jun-04-19 04:05PM  Array BioPharma to Present at the Goldman Sachs 40 Annual Global Healthcare Conference PR Newswire
09:21AM  3 Cancer Stocks Given a Lift by Amgen Motley Fool
Jun-03-19 12:18PM  Here's Why Mirati Therapeutics Is Jumping Today Motley Fool +6.43%
May-30-19 10:34AM  2 Ultra-High-Growth Biotech Stocks to Buy Now Motley Fool
May-29-19 04:05PM  Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference PR Newswire
11:55AM  Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting PR Newswire
May-23-19 08:54AM  Array BioPharma Inc. (ARRY) Shares March Higher, Can It Continue? Zacks
May-22-19 05:13PM  Array BioPharma Gains on Colorectal Cancer Study Success Zacks
08:39AM  3 Big Stock Charts for Wednesday: Oracle, Lamb Weston Holdings and TJX Companies InvestorPlace
07:34AM  The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study Benzinga
May-21-19 04:30PM  Why Dycom Industries, Array BioPharma, and Circor International Jumped Today Motley Fool +22.95%
01:55PM  Array Biopharma Tests Highs on Clinical Trial Results Investopedia
12:42PM  Here's Why Array BioPharma Is Surging Today Motley Fool
08:00AM  Array BioPharma's colorectal cancer combo treatment meets main goals Reuters
08:00AM  Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer PR Newswire
May-18-19 03:18PM  Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More Benzinga
May-16-19 02:51PM  Why Array BioPharma Shares Fell Thursday Benzinga
May-15-19 09:17PM  Edited Transcript of ARRY earnings conference call or presentation 7-May-19 1:00pm GMT Thomson Reuters StreetEvents
May-10-19 09:00AM  All You Need to Know About Array BioPharma (ARRY) Rating Upgrade to Buy Zacks
May-09-19 04:05PM  Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire
May-08-19 09:56AM  Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates Zacks
May-07-19 04:18PM  Boulder biotech firm beats expectations despite year-over-year losses on income, revenue American City Business Journals
03:23PM  Array Biopharma Inc (ARRY) Q3 2019 Earnings Call Transcript Motley Fool
09:15AM  Array BioPharma (ARRY) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:05AM  Array BioPharma: Fiscal 3Q Earnings Snapshot Associated Press
08:00AM  Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019 PR Newswire
Apr-30-19 04:05PM  Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019 PR Newswire
Apr-26-19 03:37PM  The Array BioPharma (NASDAQ:ARRY) Share Price Is Up 610% And Shareholders Are Delighted Simply Wall St.
11:25AM  Did Hedge Funds Drop The Ball On Array Biopharma Inc (ARRY) ? Insider Monkey
Mar-18-19 08:00AM  BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer PR Newswire
Mar-07-19 12:18PM  How Financially Strong Is Array BioPharma Inc. (NASDAQ:ARRY)? Simply Wall St.
Mar-06-19 07:57AM  Why Array BioPharma Stock Soared 22.9% in February Motley Fool
Mar-05-19 04:05PM  Array BioPharma to Present at the 39th Annual Cowen Health Care Conference PR Newswire
02:40PM  3 Small Caps Posting Big Gains Investopedia
Mar-04-19 08:35AM  Recent Analysis Shows Array BioPharma, Nabors Industries, Brinker International, Piedmont Office Realty Trust, Och-Ziff Capital Management Group, and Franklin Street Properties Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-26-19 01:34PM  5 Stocks Seeing Insider Selling Right Now Kiplinger
Feb-21-19 04:05PM  Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference PR Newswire
Feb-14-19 02:02PM  Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up Zacks
Feb-07-19 06:34AM  Will Array BioPharma Continue to Surge Higher? Zacks
Feb-06-19 08:40AM  Array BioPharma (ARRY) Soars: Stock Adds 11% in Session Zacks
08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 04:19PM  Array BioPharma Surges as Loss Is Narrower Than Expected TheStreet.com +10.96%
03:39PM  Here's What Sent Array BioPharma Soaring 11.3% Today Motley Fool
02:03PM  Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript Motley Fool
01:14PM  Boulder biotech firm's skin cancer drugs drive 'strong' second quarter American City Business Journals
10:00AM  Here's Why Array BioPharma (ARRY) is a Great Momentum Stock to Buy Zacks
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including a Phase III trial in BRAF-mutant colorectal cancer. Its product pipeline also includes ipatasertib, an AKT inhibitor that is in Phase III trial to treat prostate or breast cancers; selumetinib, a MEK inhibitor for cancer; larotrectinib, a PanTrk inhibitor that is in a Phase II/registration clinical trial for cancer; tucatinib, a HER2 inhibitor for breast cancer, which is in Phase II/registration trial; and ARRY-797 that is in Phase III clinical trial for Lamin A/C-related dilated cardiomyopathy. In addition, the company is developing varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric cancer; ARRY-382, a CSF1R inhibitor that is in Phase II clinical trial to treat cancer; motolimod/VTX-2337, a Toll-like receptor that is in Phase II clinical trial for cancer; and prexasertib/LY2606368, a CHK-1 inhibitor, which is in multiple Phase I or II clinical trials for cancer. Further, its drug candidates in Phase I clinical trials include GDC-0575, a CHK-1 inhibitor for cancer; LOXO-292, a RET inhibitor to treat cancer; and LOXO-195, a Trk inhibitor for cancer. Additionally, its drug candidates include Ganovo/danoprevir, a protease inhibitor for hepatitis C virus. The company was founded in 1998 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sandor VictorChief Medical OfficerJun 04Option Exercise7.30100,000730,000309,543Jun 06 04:02 PM
Sandor VictorChief Medical OfficerJun 04Sale28.51100,0002,851,000209,543Jun 06 04:02 PM
Sandor VictorChief Medical OfficerJun 03Option Exercise3.6536,134131,889245,677Jun 03 04:03 PM
Sandor VictorChief Medical OfficerJun 03Sale27.5836,134996,738209,543Jun 03 04:03 PM
Sandor VictorChief Medical OfficerMay 30Option Exercise3.6515,72857,407225,271Jun 03 04:03 PM
Sandor VictorChief Medical OfficerMay 30Sale27.5015,728432,520209,543Jun 03 04:03 PM
Sandor VictorChief Medical OfficerMay 28Option Exercise3.6546,766170,696284,458May 28 04:04 PM
Sandor VictorChief Medical OfficerMay 28Sale27.0074,9152,022,930209,543May 28 04:04 PM
Sandor VictorChief Medical OfficerMay 23Option Exercise3.6540,634148,314278,326May 28 04:04 PM
Sandor VictorChief Medical OfficerMay 23Sale26.5040,6341,076,846237,692May 28 04:04 PM
Sandor VictorChief Medical OfficerMay 21Option Exercise3.6512,60045,990250,292May 23 05:26 PM
Sandor VictorChief Medical OfficerMay 21Sale26.5012,600333,900237,692May 23 05:26 PM
Saccomano Nicholas ACSOApr 01Option Exercise0.0013,7500156,238Apr 03 04:30 PM
Squarer RonCEOApr 01Option Exercise0.0037,8130276,522Apr 03 04:31 PM
Robbins Andrew RCOOApr 01Option Exercise0.0019,688079,682Apr 03 04:31 PM
Sandor VictorChief Medical OfficerApr 01Option Exercise0.0015,6260244,624Apr 03 04:30 PM
COX CARRIE SMITHDirectorFeb 19Buy23.205,000115,9988,000Feb 21 04:30 PM
Haddock JasonCFOFeb 07Option Exercise3.7785,000320,450115,059Feb 08 06:34 PM
Saccomano Nicholas ACSOFeb 07Option Exercise3.67187,264687,509329,752Feb 08 06:32 PM
Squarer RonCEOFeb 07Option Exercise3.61110,000397,100348,709Feb 08 06:31 PM
Saccomano Nicholas ACSOFeb 07Sale21.58187,2644,041,756142,488Feb 08 06:32 PM
Squarer RonCEOFeb 07Sale21.64110,0002,380,015238,709Feb 08 06:31 PM
Haddock JasonCFOFeb 07Sale22.0585,0001,874,30130,059Feb 08 06:34 PM
LEFKOFF KYLEDirectorFeb 06Option Exercise10.4725,000261,75047,720Feb 08 07:14 PM
Robbins Andrew RCOOFeb 06Option Exercise5.70125,000712,625299,620Feb 08 06:36 PM
Haddock JasonCFOFeb 06Sale20.0011,712234,24030,059Feb 08 06:34 PM
LEFKOFF KYLEDirectorFeb 06Sale20.8410,000208,38220,000Feb 08 07:14 PM
LEFKOFF KYLEDirectorFeb 06Sale20.5125,000512,69322,720Feb 08 07:14 PM
Robbins Andrew RCOOFeb 06Sale20.03239,6264,798,51159,994Feb 08 06:36 PM
Oltmans Curtis GaleGeneral CounselFeb 05Option Exercise8.9440,000357,60055,021Feb 07 04:30 PM
Oltmans Curtis GaleGeneral CounselFeb 05Sale20.0040,000800,00015,021Feb 07 04:30 PM
Squarer RonCEOJan 31Option Exercise7.30113,438828,097352,147Feb 01 08:44 PM
Squarer RonCEOJan 31Sale18.53113,4382,101,541238,709Feb 01 08:44 PM
Squarer RonCEOJan 30Option Exercise3.61100,000361,000338,709Feb 01 08:44 PM
Squarer RonCEOJan 30Sale18.25100,0001,825,370238,709Feb 01 08:44 PM
Oltmans Curtis GaleGeneral CounselJan 29Option Exercise8.9411,10099,23415,021Feb 07 04:30 PM
Oltmans Curtis GaleGeneral CounselJan 25Option Exercise8.9414,029125,41917,950Jan 29 04:27 PM
Oltmans Curtis GaleGeneral CounselJan 25Sale18.0014,029252,5233,921Jan 29 04:27 PM
Oltmans Curtis GaleGeneral CounselJan 18Option Exercise8.941,25111,1845,172Jan 23 04:47 PM
Oltmans Curtis GaleGeneral CounselJan 18Sale18.001,25122,5183,921Jan 23 04:47 PM
Oltmans Curtis GaleGeneral CounselJan 15Option Exercise8.9419,720176,29723,641Jan 17 04:58 PM
Oltmans Curtis GaleGeneral CounselJan 15Sale18.0619,720356,1393,921Jan 17 04:58 PM
Sandor VictorChief Medical OfficerDec 27Sale14.056,26888,091228,998Jan 02 04:32 PM
Robbins Andrew RCOODec 16Option Exercise0.0027,0510186,518Dec 18 07:48 PM
Saccomano Nicholas ACSODec 16Option Exercise0.0012,469074,162Dec 18 07:49 PM
Sandor VictorChief Medical OfficerDec 16Option Exercise0.0023,3460245,644Dec 18 07:49 PM
Haddock JasonCFODec 16Option Exercise0.0011,387046,780Dec 18 07:48 PM
Squarer RonCEODec 16Option Exercise0.0048,4370260,012Dec 18 07:48 PM
Oltmans Curtis GaleGeneral CounselDec 16Option Exercise0.007,00007,000Dec 18 07:48 PM
Sandor VictorChief Medical OfficerDec 03Option Exercise3.65127,397464,999337,483Dec 06 04:02 PM
Sandor VictorChief Medical OfficerDec 03Sale16.21115,1851,867,045222,298Dec 06 04:02 PM
COX CARRIE SMITHDirectorNov 01Buy16.873,00050,5953,000Nov 05 04:37 PM
VAN LUNSEN GIL JDirectorSep 19Option Exercise5.9518,000107,10037,297Sep 21 04:18 PM
VAN LUNSEN GIL JDirectorSep 19Sale14.7618,000265,68419,297Sep 21 04:18 PM
Sandor VictorChief Medical OfficerSep 04Sale15.389,687148,938210,086Sep 05 04:18 PM
VAN LUNSEN GIL JDirectorAug 15Option Exercise5.7121,500122,85040,797Aug 17 04:46 PM
Haddock JasonCFOAug 15Sale13.9220,000278,40035,393Aug 17 04:46 PM
VAN LUNSEN GIL JDirectorAug 15Sale13.9221,500299,28019,297Aug 17 04:46 PM
Haddock JasonCFOJul 30Option Exercise3.7751,525194,24980,393Jul 31 04:57 PM
Haddock JasonCFOJul 30Sale14.8725,000371,75055,393Jul 31 04:57 PM
VAN LUNSEN GIL JDirectorJul 18Option Exercise5.3621,500115,23040,797Jul 19 04:26 PM
VAN LUNSEN GIL JDirectorJul 18Sale16.5621,500356,04019,297Jul 19 04:26 PM
LEFKOFF KYLEDirectorJul 06Option Exercise5.5450,000277,00067,720Jul 06 04:06 PM
LEFKOFF KYLEDirectorJul 06Sale17.4550,000872,50017,720Jul 06 04:06 PM
Robbins Andrew RCOOJun 27Option Exercise0.0032,0680191,535Jun 29 04:22 PM
Saccomano Nicholas ACSOJun 27Option Exercise0.0011,453066,731Jun 29 04:22 PM
Sandor VictorChief Medical OfficerJun 27Option Exercise0.0017,4400227,526Jun 29 04:21 PM
Squarer RonCEOJun 27Option Exercise5.66218,5061,236,094352,200Jun 29 04:22 PM
Squarer RonCEOJun 27Sale17.96184,2533,309,429211,575Jun 29 04:22 PM
Robbins Andrew RCOOJun 27Sale17.7417,964318,681159,467Jun 29 04:22 PM
open in yahoo | open in reuters | open in google